79 related articles for article (PubMed ID: 21715165)
1. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.
Zapf CW; Bloom JD; Li Z; Dushin RG; Nittoli T; Otteng M; Nikitenko A; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Olland A; Johnson M; Levin JI
Bioorg Med Chem Lett; 2011 Aug; 21(15):4602-7. PubMed ID: 21715165
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Jun; 21(12):3627-31. PubMed ID: 21605975
[TBL] [Abstract][Full Text] [Related]
3. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
[TBL] [Abstract][Full Text] [Related]
4. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Otteng M; Ingalls C; Golas JM; Liu H; Lucas J; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Jun; 21(11):3411-6. PubMed ID: 21515049
[TBL] [Abstract][Full Text] [Related]
5. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G
Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158
[TBL] [Abstract][Full Text] [Related]
6. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies.
Day JE; Sharp SY; Rowlands MG; Aherne W; Lewis W; Roe SM; Prodromou C; Pearl LH; Workman P; Moody CJ
Chemistry; 2010 Sep; 16(34):10366-72. PubMed ID: 20661961
[TBL] [Abstract][Full Text] [Related]
8. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
9. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
[TBL] [Abstract][Full Text] [Related]
10. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
[TBL] [Abstract][Full Text] [Related]
13. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
14. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
Yamazaki S; Nguyen L; Vekich S; Shen Z; Yin MJ; Mehta PP; Kung PP; Vicini P
J Pharmacol Exp Ther; 2011 Sep; 338(3):964-73. PubMed ID: 21680888
[TBL] [Abstract][Full Text] [Related]
16. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
Uno T; Kawai Y; Yamashita S; Oshiumi H; Yoshimura C; Mizutani T; Suzuki T; Chong KT; Shigeno K; Ohkubo M; Kodama Y; Muraoka H; Funabashi K; Takahashi K; Ohkubo S; Kitade M
J Med Chem; 2019 Jan; 62(2):531-551. PubMed ID: 30525599
[TBL] [Abstract][Full Text] [Related]
18. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.
Bussenius J; Blazey CM; Aay N; Anand NK; Arcalas A; Baik T; Bowles OJ; Buhr CA; Costanzo S; Curtis JK; DeFina SC; Dubenko L; Heuer TS; Huang P; Jaeger C; Joshi A; Kennedy AR; Kim AI; Lara K; Lee J; Li J; Lougheed JC; Ma S; Malek S; Manalo JC; Martini JF; McGrath G; Nicoll M; Nuss JM; Pack M; Peto CJ; Tsang TH; Wang L; Womble SW; Yakes M; Zhang W; Rice KD
Bioorg Med Chem Lett; 2012 Sep; 22(17):5396-404. PubMed ID: 22877636
[TBL] [Abstract][Full Text] [Related]
19. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
